Live feed08:00:00·141dPRReleasevia QuantisnowFate Therapeutics Presents Updated Phase 1 Clinical Data of FT819 Off-the-shelf CAR T-cell Product Candidate for Systemic Lupus Erythematosus and Preclinical Advances in Next-Generation Off-the-Shelf CAR T-cell ProgramsByQuantisnow·Wall Street's wire, on your screen.FATE· Fate Therapeutics Inc.Health Care
